10 Best Biotech Penny Stocks to Buy Now
In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities.
C4 Therapeutics Inc. (CCCC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lynx1 Capital Management Weston Nichols | 6,880,527 | $39,219,004 | 13.89% | |
| 2. | Soleus Capital Guy Levy | 6,603,996 | $37,642,777 | +63% | 2.91% |
| 3. | RA Capital Management Peter Kolchinsky | 4,878,000 | $27,804,600 | 0.32% | |
| 4. | OrbiMed Advisors Samuel Isaly | 4,377,900 | $24,954,030 | +190% | 0.45% |
| 5. | Commodore Capital Egen Atkinson And Michael Kramarz | 3,410,384 | $19,439,189 | 1.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.60 | 5,667 | Director | 5,667 | 2023-02-08 | Filing | |
| $8.40 | 10,000 | Officer, Director | 10,000 | 2022-04-12 | Filing | |
| $19.00 | 5,263 | Officer | 5,263 | 2020-10-06 | Filing | |
| $19.00 | 5,030 | Large Shareholder, Director | 5,030 | 2020-10-06 | Filing | |
| $19.00 | 1,315 | Director | 15,994 | 2020-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.66 | 1,054 | Officer | 15,000 | 2022-01-04 | Filing | |
| $31.59 | 13,946 | Officer | 16,054 | 2022-01-04 | Filing | |
| $30.25 | 755 | Director | 10,952 | 2021-12-17 | Filing | |
| $40.11 | 755 | Director | 11,707 | 2021-11-19 | Filing | |
| $44.94 | 755 | Director | 12,462 | 2021-10-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,138,949 | $40,335,062 | 0.22% | |
| 2. | 2,137,381 | $12,076,203 | 0.13% | |
| 3. | 1,999,401 | $11,296,616 | 0% | |
| 4. | 1,803,433 | $10,189,397 | 0% | |
| 5. | 1,675,097 | $9,464,298 | 0% |
News See All
Here’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
11 Hot Healthcare Stocks To Buy Now
In this article, we will be taking a look at 11 hot healthcare stocks to buy now.
12 Best High Risk Penny Stocks to Buy Now
Investors are jubilant over Nvidia crushing analyst estimates in its latest quarterly report.
Hedge Fund and Insider Trading News: Accendo Capital, Skye Capital, Vivaris Capital, ARR Investment Partners, C4 Therapeutics Inc (CCCC), and More
Stockholm (HedgeNordic) – Activist investor Accendo Capital has expanded its investment team by hiring Nicholas Bianco as a portfolio manager.
Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy?
In this article we will analyze whether C4 Therapeutics, Inc.
Hedge Funds Are Piling Into C4 Therapeutics, Inc. (CCCC)
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June.
Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy Now?
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.